Citation
Villasis-Keever, Miguel A., et al. "Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. a Randomized Clinical Trial." Archives of Medical Research, vol. 53, no. 4, 2022, pp. 423-430.
Villasis-Keever MA, López-Alarcón MG, Miranda-Novales G, et al. Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial. Arch Med Res. 2022;53(4):423-430.
Villasis-Keever, M. A., López-Alarcón, M. G., Miranda-Novales, G., Zurita-Cruz, J. N., Barrada-Vázquez, A. S., González-Ibarra, J., Martínez-Reyes, M., Grajales-Muñiz, C., Santacruz-Tinoco, C. E., Martínez-Miguel, B., Maldonado-Hernández, J., Cifuentes-González, Y., Klünder-Klünder, M., Garduño-Espinosa, J., López-Martínez, B., & Parra-Ortega, I. (2022). Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial. Archives of Medical Research, 53(4), 423-430. https://doi.org/10.1016/j.arcmed.2022.04.003
Villasis-Keever MA, et al. Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. a Randomized Clinical Trial. Arch Med Res. 2022;53(4):423-430. PubMed PMID: 35487792.
TY - JOUR
T1 - Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial.
AU - Villasis-Keever,Miguel A,
AU - López-Alarcón,Mardia G,
AU - Miranda-Novales,Guadalupe,
AU - Zurita-Cruz,Jessie N,
AU - Barrada-Vázquez,Aly S,
AU - González-Ibarra,Joaquín,
AU - Martínez-Reyes,Monserrat,
AU - Grajales-Muñiz,Concepción,
AU - Santacruz-Tinoco,Clara E,
AU - Martínez-Miguel,Bernardo,
AU - Maldonado-Hernández,Jorge,
AU - Cifuentes-González,Yazmín,
AU - Klünder-Klünder,Miguel,
AU - Garduño-Espinosa,Juan,
AU - López-Martínez,Briseida,
AU - Parra-Ortega,Israel,
Y1 - 2022/04/18/
PY - 2022/02/28/received
PY - 2022/03/25/revised
PY - 2022/04/11/accepted
PY - 2022/4/30/pubmed
PY - 2022/5/31/medline
PY - 2022/4/29/entrez
KW - 25-hydroxyvitamin D3
KW - COVID-19
KW - Healthcare workers
KW - SARS-CoV-2
KW - Vitamin D
SP - 423
EP - 430
JF - Archives of medical research
JO - Arch Med Res
VL - 53
IS - 4
N2 - BACKGROUND: Associations between vitamin D (VD) deficiency and the risk of SARS-CoV-2 infection have been documented in cross-sectional population studies. Intervention studies in patients with moderate to severe COVID-19 have failed to consistently document a beneficial effect. OBJECTIVE: To determine the efficacy and safety of VD-supplementation in the prevention of SARS-CoV-2 infection in highly exposed individuals. METHODS: A double-blind, parallel, randomized trial was conducted. Frontline healthcare workers from four hospitals in Mexico City, who tested negative for SARS-CoV-2 infection, were enrolled between July 15 and December 30, 2020. Participants were randomly assigned to receive 4,000 IU VD (VDG) or placebo (PG) daily for 30 d. RT-PCR tests were taken at baseline and repeated if COVID-19 manifestations appeared during follow-up. Serum 25-hydroxyvitamin D3 and antibody tests were measured at baseline and at day 45. Per-protocol and intention-to-treat analysis were conducted. RESULTS: Of 321 recruited subjects, 94 VDG and 98 PG completed follow-up. SARS-CoV-2 infection rate was lower in VDG than in PG (6.4 vs. 24.5%, p <0.001). The risk of acquiring SARS-CoV-2 infection was lower in the VDG than in the PG (RR: 0.23; 95% CI: 0.09-0.55) and was associated with an increment in serum levels of 25-hydroxyvitamin D3 (RR: 0.87; 95% CI: 0.82-0.93), independently of VD deficiency. No significant adverse events were identified. CONCLUSIONS: Our results suggest that VD-supplementation in highly exposed individuals prevents SARS-CoV-2 infection without serious AEs and regardless of VD status.
SN - 1873-5487
UR - https://www.unboundmedicine.com/medline/citation/35487792/full_citation
DB - PRIME
DP - Unbound Medicine
ER -
